Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
Journal Impact Factor (JIF 2025) – 2.5
Journal Citation Indicator (JCI 2025) – 0.40
Scopus CiteScore (2025) – 4.2
Index Copernicus Value (ICV 2024) – 161.00
MNiSW – 70 pts
ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/219333

Publication type: original article

Thematic category: Psychiatry; health sciences; public health

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:


Bejda G, Korol A, Kułak-Bejda A, et al. Changes in bio-psycho-social aspects of male aging: A comparative study of hospitalized patients (2013–2023) [published online as ahead of print on August 3, 2026]. Adv Clin Exp Med. 2026. doi:10.17219/acem/219333

Changes in bio-psycho-social aspects of male aging: A comparative study of hospitalized patients (2013–2023)

Grzegorz Bejda1,A,B,C,D,F, Agnieszka Korol2,A,B,F, Agnieszka Kułak-Bejda3,B,F, Anna Ślifirczyk4,B,F, Edyta Rysiak5,B,F, Wojciech Kułak6,B,F, Elżbieta Krajewska-Kułak7,A,B,C,F

1 School of Medical Science in Bialystok, Poland

2 Department of Health Science, John Paul II University, Biała Podlaska, Poland

3 Department of Psychiatry, Medical University of Bialystok, Poland

4 Department of Health Science, WSEI University, Lublin, Poland

5 Department of Medicinal Chemistry, Medical University of Bialystok, Poland

6 Department of Pediatric Rehabilitation, Medical University of Bialystok, Poland

7 Department of Integrated Medical Care, Medical University of Bialystok, Poland

Graphical abstract


Graphical abstracts

Highlights


• Perceptions of aging in men remained stable over a 10-year period in Polish men.
• Psychological symptoms and sexual dysfunction are common in aging men.
• Andropause is widely perceived as a natural process related to declining testosterone.
• Knowledge gaps about male aging persist despite good self-rated health and self-efficacy.

Abstract

Background. Owing to medical advances and improved living conditions, life expectancy continues to increase. Consequently, population aging poses growing challenges for healthcare systems.

Objectives. The aim of this study was to assess whether men’s perceptions of aging have changed between 2013 and 2023.

Materials and methods. A cross-sectional comparative study was conducted in 2013 and 2023 using identical research tools and inclusion criteria. Participants were randomly selected from hospitalized patients in the Podlaskie Province, Poland. The following instruments were used: an original questionnaire, the Satisfaction with Life Scale (SWLS), the Generalised Self-Efficacy Scale (GSES), the Beck Depression Inventory (BDI), the Inventory of Health Behaviour (IHB), the Androgen Deficiency in Aging Male questionnaire (ADAM), and the Aging Males’ Symptoms Scale (AMS).

Results. Most respondents in both 2013 and 2023 associated old age with declining testosterone levels and considered it to begin after the age of 75. Men generally rated their health as good and regarded andropause as a natural process. Psychological symptoms of aging were reported by 80.5% of respondents in 2013 and 75.9% in 2023, while sexual dysfunction was reported by 65.8% and 63.3%, respectively. More than half of the respondents had no depressive symptoms according to the BDI. Men with high self-efficacy predominated in both study periods.

Conclusions. Respondents’ knowledge of the aging process remains incomplete and often inaccurate. Despite this, men generally rated their health positively and perceived andropause as a natural process. Psychological symptoms of aging and sexual dysfunction were reported by a substantial proportion of participants.

Key words: aging, aging male, andropause, quality of life, mental health

Background

As emphasized by Królikowska,1 population health can be assessed using various indicators and analyzed in relation to gender, both as a factor differentiating the health status of populations and as a key determinant of health inequalities between women and men. Within this framework, 2 main correlations can be distinguished: the 1st related to biological differences (sex) and the 2nd to sociocultural factors (gender). Health outcomes may improve when individual and group health behaviors, including risk-related behaviors, are less influenced by gender-related factors.

Medical advances and improved living conditions have led to increased life expectancy, making population aging a global issue. United Nations projections2 indicate that the proportion of children and young people in developing countries will decrease from approx. 33% in 2000 to 26% in 2025. In Europe, it is projected that by 2060, the population aged 65 and over will increase by around 12 percentage points, reaching 29.5% of the total population.3 In Poland, by 2035, individuals in the so-called “third age” are expected to account for approx. 23% of the population, increasing to as much as 34.5% in the 2nd half of the century. Poland is projected to become one of the 3 fastest-aging countries in the European Union (EU), with older adults comprising around 35% of the population by 2050.3 Therefore, measuring population health is crucial for several reasons.4 Population health measures provide essential information to assess and improve community health. Monitoring population health allows the identification of health problems within communities. It helps identify patterns, trends, and disparities related to diseases, risk factors, and social determinants of health. Data on population health inform policy development. Policymakers rely on this information to make informed decisions about resource allocation, preventive measures, and interventions. Shared measurement systems ensure accountability across various sectors, including public health, healthcare, and private entities. Integrating efforts to improve population health is more effective when everyone uses appropriate, standardized measures. Combined with epidemiology, population health data provides insights into disease patterns, risk factors, and health service utilization. These insights guide public health strategies and interventions.

Medical professionals have underestimated the issue of male aging and andropause. The concept of andropause remains relatively unfamiliar among both men and healthcare providers.5 The term is often used to describe a condition comparable to female menopause. From a biopsychosocial perspective, andropause refers to the aging process and the development of various disorders affecting multiple aspects of an individual’s functioning. Other terms, such as viropause, male menopause, or low testosterone syndrome, as well as acronyms such as ADAM (androgen deficiency in aging males), PEDAM (partial endocrine deficiency in aging males), and PADAM (partial androgen deficiency in aging males), have been used in the literature but have not gained widespread acceptance. While menopause in women is typically characterized by pronounced symptoms, andropause in men usually presents more subtly. However, these symptoms are not universal and may result from factors other than testosterone decline.

Falling testosterone levels lead to alterations in sexual and psychological functions and body composition. These changes comprise mood swings, depression, poor concentration and memory, anxiety and irritability, decreased libido, erectile dysfunction, reduced muscle mass and strength, loss of body hair, and osteoporosis.6, 7

Men’s perceptions of the aging process vary according to age.8 Diehl et al. investigated how self-perceptions of aging changed over time in middle-aged and older adults, following them for up to 21 years. The 3 dimensions included participants’ regarding physical losses, social losses, and ongoing development. The study revealed that, beginning around age 65, participants experienced increased perceptions of physical and social losses, which became more pronounced with advancing age. Participants around the age of 55 began to report fewer perceptions of ongoing development, with a steeper decline observed after age 70.

Existing research on male aging and andropause is inconsistent.9 Despite extensive investigation of the male–female health paradox, it remains unclear whether behavioral factors or biological and social differences primarily account for gender disparities in health. Andropause is commonly used to describe age-related declines in androgen levels, vitality, and reproductive function in men. However, this concept is not universally accepted, as it is difficult to distinguish the effects of aging from other factors such as stress, illness, or medication use. Some researchers question the validity of the concept, whereas others recognize subtle changes in sexual function, cognitive performance, fatigue, and body composition in older men. Testosterone replacement therapy may be associated with adverse effects and should be used with caution. Although it is not intended to treat conditions such as obesity, diabetes, or physical inactivity, identifying and treating hypogonadism may support improvements in overall health and lifestyle. To our knowledge, there is a lack of long-term research on how men in Poland perceive and understand andropause and aging.

Objectives

This study aimed to examine whether men’s perceptions of aging have changed between 2013 and 2023. The analysis included biopsychosocial aspects of aging, such as life satisfaction, self-efficacy, risk of depression, health-related behaviors, quality of life, and aging symptoms.

The following hypotheses were formulated:

Hypothesis 1: There is a significant difference in the perception of aging between men in 2013 and 2023, with men in 2023 demonstrating a more positive outlook on aging.

Hypothesis 2: The prevalence of depressive symptoms is higher among men experiencing andropause in 2023 compared to 2013.

Hypothesis 3: Knowledge and awareness of andropause have increased significantly among men between 2013 and 2023.

Materials and methods

Study design and population

This cross-sectional comparative study was conducted in 2013 and 2023 and included 308 male participants in 2013 and 349 in 2023. A purposive sampling method was applied. Sample size was estimated to ensure a 95% confidence level with a margin of error of ±5%, indicating that at least 172 participants were required. Identical research tools and inclusion criteria were used in both study periods. Participants were purposefully selected from patients hospitalized at the Teaching Hospital of the Medical University of Bialystok (Poland) and the Provincial Specialist Hospital in Biała Podlaska (Poland), as well as from students at the Pope John Paul II State School of Higher Education in Biała Podlaska, the Medical University of Bialystok, and the University of Medical Sciences in Bialystok. Questionnaires were administered to participants by the study authors. Inclusion criteria were: male sex, age 18–90 years, willingness to provide informed consent, and ability to complete the questionnaires. Exclusion criteria included age below 18 or above 90 years, lack of informed consent, and inability to complete the questionnaires.

All methods were carried out in accordance with relevant guidelines and regulations. Ethical approval was obtained from the Bioethics Committee of the Medical University of Bialystok for both study periods: approval No. R-I-022/55/2012 (2013) and approval No. APK.002.515.2021 (2023). Participation in the survey was voluntary, and all participants could withdraw from the study at any time without any obligation to continue. No personally identifiable data were collected.

In 2013, 340 questionnaires were distributed, and 308 were completed, resulting in a response rate of 90%. In 2023, 370 questionnaires were distributed, and 349 were completed, yielding a response rate of 94%. Significant differences were observed between the 2013 and 2023 groups in terms of age, residence, household composition, social and living conditions, and education. No significant differences were found between the groups regarding marital status. Details are presented in Table 1.

The COVID-19 pandemic had a profound impact on the psychological, social, and physical environment.10 Lockdowns, social distancing, and restrictions on gatherings substantially increased feelings of loneliness. Among older men, this isolation may have contributed to increased symptoms of depression. Chronic stress and uncertainty are well-established risk factors for depressive disorders. Health anxiety was one of the most significant psychological features of the COVID-19 pandemic. This period contributed to the exacerbation of both mental and physical health conditions.

Data collection

The study used a self-developed questionnaire designed for men. It covered topics such as perceptions of old age and its potential advantages, perception of one’s chronological age, willingness to live to old age, self-assessment of health, and frequency of medical care. The questionnaire also included items on symptoms associated with aging (psychological, somatic-vegetative, sexual, and cognitive), knowledge of hormonal changes during male aging, opinions on hormone therapy and its effects, willingness to undergo such therapy, and awareness of and sources of information about andropause. Additional items addressed the perceived usefulness of this information, interest in expanding knowledge about andropause, preferred educational sources, and characteristics associated with men experiencing andropause. All scales used in the study have been validated in Poland.

Instruments

SWLS – The Satisfaction with Life Scale

It was published by Diener, Emmons, Larsen, and Griffin (and in the Polish version by Juczyński). The SWLS is a 5-item, 7-point Likert scale that assesses global cognitive judgments of one’s life satisfaction as a single factor.11 As opposed to the emotional or affective component, the scale was developed to represent the judgment or cognitive component and thus does not measure positive or negative affect. The SWLS is stable yet sensitive enough to detect changes in life satisfaction during psychotherapy or in response to significant life events. The reliability coefficient (Cronbach’s α) of the SWLS is 0.81, and the consistency index is 0.86.

Respondents rate the extent to which each statement relates to their life, where: 1 – strongly disagree, 2 – disagree, 3 – slightly disagree, 4 – neither agree nor disagree, 5 – slightly agree, 6 – agree, and 7 – strongly agree. The scores are summed, and the overall score indicates the level of life satisfaction. Scoring ranges from 5 to 35, whereby higher scores indicate greater life satisfaction: a score of 5–9 – extremely dissatisfied with life, a score of 10–14 – very dissatisfied with life, a score of 15–19 – slightly dissatisfied with life, a score of 20 – neither satisfied nor dissatisfied with life, a score of 21–25 – slightly satisfied with life, a score of 26–30 – very satisfied with life, and a score of 31–35 – extremely satisfied with life.11

GSES – Standardized Generalized Self-Efficacy Scale

The scale was developed by Schwarzer, Jerusalem, and Juczyński.11 Self-efficacy is defined as the ability to set challenging goals, commit to difficult tasks, and strive to achieve them, and is considered an important predictor of behavior change. The scale demonstrates high reliability, with a Cronbach’s α coefficient of 0.85. It consists of items rated on a 4-point Likert scale: 1 – not at all true, 2 – hardly true, 3 – moderately true, and 4 – exactly true. Scores range from 10 to 40, with higher scores indicating greater self-efficacy.11

Standardized Beck Depression Inventory

The Beck Depression Inventory (BDI) is one of the most widely used self-report scales for assessing depression worldwide. Since its development in 1961, it has been employed in over 14,000 empirical studies. The advantages of the BDI include good internal consistency, sensitivity to change, broad construct validity, the ability to differentiate between depressed and non-depressed individuals, and cross-cultural reliability. Its main limitations include the lack of representative norms, the potential subjectivity of interpretation, and concerns regarding its factorial validity. Cronbach’s α coefficient was 0.91 in the overall sample and 0.93 among patients with depression. Scores are interpreted as follows: 0–11 – no depression; 12–26 – mild depression; 27–49 – moderate depression; and 50–63 – severe depression.12

IHB – Standardized Inventory of Health Behavior

The instrument was published by Juczyński. The instrument was developed based on existing literature relating to lifestyle modifications. A high score on the scale indicates poor health behavior. In other words, the higher the scale score, the poorer the health behavior, and vice versa. The IHB internal consistency, measured with Cronbach’s α, is 0.85 for the whole inventory, while its 4 subscales range from 0.60 to 0.65. Respondents indicated how often they performed specific health-related activities, rating each behavior listed in the inventory on a 5-point scale: 1 – almost never, 2 – rarely, 3 – occasionally, 4 – often, and 5 – almost always. The numerical values marked by the respondents were summed to obtain a score between 24 and 120. The higher the score obtained by the respondent, the higher the intensity of their declared health behavior.11

The standardized Morley Questionnaire (Androgen Deficiency in the Aging Male – ADAM)

The ADAM questionnaire consists of 10 “yes or no” questions concerning symptoms of androgen deficiency. These “yes or no” questions, although effective in identifying symptoms associated with androgen deficiency, provide no information about the severity of these symptoms. Thus, there is no simple, noninvasive way to monitor treatment response using this tool alone unless symptoms completely resolve. It does not provide a clear answer as to whether the patient suffers from andropause syndrome. However, affirmative answers to questions 1–7 or to 3 other questions suggest that the complaints result from hormonal disorders.13, 14

AMS – The Aging Males’ Symptoms Scale – Standardized Aging Male Symptoms Scale

The Polish version was provided by Heinemann. The scale assesses symptoms related to male physiological and psychological aging. It contains 17 different symptoms typical of the andropause period. Respondents assess whether each symptom has occurred in themselves using a scale from 1 to 5, where 1 – no symptom, 2 – mild, 3 – moderate, 4 – severe, and 5 – extreme. Respondents may also report other symptoms not included in the scale. The scale is divided into 3 subscales corresponding to different groups of disorders: somatic, psychological, and sexual. Somatic symptoms include general deterioration of health, muscle and joint pain, sleep problems, fatigue, exhaustion, and decreased strength: no or slight symptoms are defined by scores less than or equal to 8; mild symptoms by scores of 9–12; moderate by scores of 13–18; and severe by scores of 19 and above. Psychological symptoms include anxiety, nervousness, irritability, depression, and burnout: no or slight symptoms are defined by scores less than or equal to 5; mild by scores of 6–8; moderate by scores of 9–11; and severe by scores of 12 and above. Sexual symptoms include decreased ability to perform sexually, reduced number of morning erections, and decreased libido; this group also includes reduced beard growth: no or minor symptoms are defined by scores less than or equal to 5; mild by scores of 6–7; moderate by scores of 8–10; and severe by scores of 11 or more.15, 16

Statistical analyses

The statistical analysis was conducted using Statistica v. 13 PL (StatSoft Poland, Cracow, Poland). The normality of the data was assessed using the Kolmogorov–Smirnov test. The data were not normally distributed; therefore, the Mann–Whitney U test was used to compare numeric data, and Pearson’s χ2 test with Yates’ correction was used to compare percentages. Fisher’s exact test was applied when any cell had an expected count of 5 or fewer. A significance level of p < 0.05 was considered statistically significant.

The relationship between categorical variables was examined using contingency table analysis. To determine whether an observed association between the variables was statistically significant, Pearson’s χ2 test of independence was employed. A p < 0.05 was considered indicative of a significant association. We used 2 × 2, 3 × 2, 4 × 2, and 5 × 2 contingency tables.

Results

The evaluated groups showed significant differences in attitudes toward old age, beliefs about successful aging, and self-identification with chronological age. Details are presented in Table 2.

In 2013, men reported significantly (p < 0.001) more frequent mental symptoms, such as hyperactivity (16.9%), nervousness and anger (37.3%), mood swings and irritability (36.7%), and discouragement (36.7%), than in 2023. Moreover, in 2023, respondents reported significantly (p < 0.001) more frequent depression (67.0%), inability to experience joy (39.8%), lack of vitality (39.5%), and a sense of “emptiness” (38.7%) than in 2013. In 2013, men reported significantly (p < 0.001) more frequent physical symptoms, such as muscular pain (42.2%), excessive sweating (20.5%), and palpitations (38.6%) than in 2023. In 2023, regarding physical symptoms, respondents reported significantly higher (p < 0.001) rates of weakness (60.5%), fatigue (47.3%), and decreased libido (90%) than in 2013. Details are presented in Table 3.

Significant (p < 0.001) differences between the groups were found in respondents’ self-rated health assessments. Also, regarding the frequency of seeking medical care, we noted some differences. More often, respondents sought medical care “when needed”. Details are presented in Table 4.

In 2023, respondents were more likely (87.7%) to say they knew what “andropause” meant than in 2013. Significant (p < 0.001) differences were found between the groups regarding andropause. In 2023, most men (58.7%) reported that andropause was natural significantly more often (p < 0.001) than in 2013. In 2013, men had significantly (p < 0.001) more difficulty expressing their opinions on andropause. In 2023, more respondents described men after andropause as sensitive (27.8%) and professionally active (23.5%). In 2023, men more frequently described post-andropause men as sexually inactive (42.3%) and unfit (35.8%) compared to 2013. Details are presented in Table 5.

Significant differences (p < 0.001) were observed between the groups regarding the perceived benefits of hormone therapy. In 2013, most respondents (58.8%) reported that they were unsure whether hormone therapy was beneficial during andropause (p < 0.001). In 2023, men reported significantly more frequent positive effects of hormone therapy (p < 0.001), including improved sleep (44.7%), enhanced erections (42.1%), and reduced fat mass (54.7%). Details are presented in Table 6.

Study respondents reported similar levels of life satisfaction. In 2023, they had a much higher sense of self-efficacy than men did in 2013. Beck Depression Inventory data indicate that respondents in 2013 had significantly lower scores than those in 2023 (p < 0.001), with no signs of depression. In 2013, respondents’ health behavior levels were significantly higher (p < 0.01) than those in 2023. In 2023, respondents reported a significantly higher frequency of andropause symptoms (p < 0.001) than in 2013, as measured using the Morley scale. Participants experienced physical and mental symptoms and sexual signs of andropause at a similar level in 2013 and 2023 (Table 7).

Respondents reported that the press (15.6% in 2013) and the Internet (26.4% in 2023) were the primary sources of information about andropause (p < 0.001). More than half of the participants (53.6%) reported greater interest in learning more about andropause in 2023 than in 2013 (p < 0.001). In 2013, 57.7% of respondents believed that physicians should educate all men about andropause (p < 0.01). By 2023, 69.6% suggested this role for psychologists. Significant (p < 0.001) differences between the groups were found regarding willingness to learn more about andropause. Details are presented in Table 8.

Discussion

Population aging impacts healthcare systems, social structures, and the economy. Increased longevity leads to greater demand for healthcare services, as older individuals often manage multiple chronic conditions requiring ongoing medical care. Consequently, healthcare systems must allocate resources effectively across hospital funding, long-term care, and specialized geriatric services to meet these demands. The healthcare workforce also faces challenges in addressing the complex needs of older patients.17, 18 Additionally, social issues such as isolation and loneliness can become more prevalent among older adults, potentially contributing to mental health problems.19

Andropause is a natural part of the aging process in men, yet public awareness of the condition remains relatively low. Consistent with this general observation, the current study found that participating men demonstrated limited knowledge about andropause in both 2013 and 2023. Consistent with previous research,20, 21, 22, 23 our results show low knowledge about male andropause. However, knowledge levels vary internationally. For example, in an Iranian study,20 73.6% of men reported andropause symptoms, while 73.6% reported minimal understanding of the condition. That study20 also found that knowledge of andropause correlated with education, occupation, and income, and that symptom prevalence was significantly associated with body mass index (BMI) and occupation.

Andropause awareness differs significantly across populations. A Nigerian study21 found that nearly half (45.1%) of respondents lacked knowledge of andropause, despite 96% experiencing typical physical symptoms, which reportedly peaked between the ages of 54 and 62. Conversely, knowledge was extremely low among males in India,22 where only 2.2% knew the term “andropause” and 11.4% were aware of its treatment. In Sweden,23 over half (65.4%) had heard of the “male climacteric”, associating it mainly with reduced libido and erectile function. Showing greater familiarity, 79.4% of Chinese male respondents in Hong Kong24 recognized the term “andropause”.

In terms of mental symptoms associated with old age, in 2013 the respondents mentioned nervousness and anger, whereas in 2023 they reported depression. Our findings are consistent with previous reports.24, 25 Chinese males reported irritability more often (72.5%). Regarding physical symptoms of andropause, they reported loss of energy (66.5%) and loss of libido (60.7%). In the present study, males reported physical symptoms more often in 2013, including joint pain, and in 2023, memory impairment.

According to Ashat et al.,22 52% of men aged 40–70 experience some form of sexual dysfunction. In 2013, 46% of respondents and 91% in 2023 reported reduced libido. Similarly, a Chinese study25 reported that 60.7% of respondents associated loss of libido with andropause.

Cognitive impairment was indicated in both studies, while other reported symptoms of old age included hypertension in 2013 and hearing impairment in 2023. The study found that men rated their health positively more often in 2023 than in 2013 (87.1% vs 50.6%). In comparison, a Polish study showed that men attending the University of the Third Age reported lower health ratings.

The literature suggests that optimism and life satisfaction positively influence health outcomes, as individuals with an optimistic outlook are more likely to engage in preventive healthcare measures, effectively manage illnesses, and recover more quickly. A study conducted by the Centre for Public Opinion Research,26 involving a representative sample of 1,018 adult residents of Poland, revealed that 75% of participants were satisfied with their lives. Men reported higher satisfaction levels than women. Similarly, the current study demonstrated that respondents in both 2013 and 2023 reported considerable life satisfaction.

Based on data obtained by Pryczek and Bielawska-Batorowicz,27 over 90% of respondents reported that andropause symptoms vary between men and do not prevent them from remaining professionally active. They believed that the condition is natural and does not require hospitalization. Additionally, a Chinese study24 found that 88.2% of respondents reported that andropause is a natural part of the aging process. Similarly, in our study, conducted in 2013 and 2023, respondents considered andropause a natural phenomenon.

Declining male hormone levels have been associated with changes such as depression, loss of libido, sexual dysfunction, and alterations in body composition. However, healthcare professionals29 reported infrequent inquiries from patients regarding low testosterone levels. In the current study, a significant proportion of men in 2013 and 2023 reported a correlation between advancing age and decreased testosterone levels (76.6% vs 75.1%). Testosterone replacement therapy is one of the key issues in the treatment of men with andropause28.

The AMS and Morley scales are commonly used to assess male reproductive health and andropause symptoms. Our study is consistent with previous reports based on the AMS and Morley scales.29, 30, 31, 32 Furthermore, Jankowska et al.32 found that age and social position are major determinants of symptom intensity in aging men, as measured using the AMS scale in Poland. Age is a significant determinant affecting the severity of depressive symptoms in male populations.33, 34, 35 Our study found that depression rates and risks were moderate. In a study conducted in China, the incidence of depression was 14%.35 In Turkey, it was 38.7%.36 In an Iranian study,37 there was a significant association between andropause and sexual quality of life among older men.

The stronger the sense of self-efficacy and the associated expectations, the greater the confidence in one’s ability to achieve positive outcomes. The study by Byra38 found that men had higher levels of self-efficacy than women. Our study also confirmed this, as men with high self-efficacy predominated in both 2013 and 2023.

In the context under discussion, it seems important to analyze men’s level of knowledge about aging and the sources of information on this topic. In our study, the primary sources of knowledge about andropause were the media and the Internet. In contrast, according to Yan’s study,24 the main source of information on andropause was the mass media (76.4%), followed by doctors and healthcare providers (10.8%). However, the Internet was the least common source of information (1.0%).

There is limited research in the Polish literature on men’s views of aging, their awareness of its symptoms, and related education. This gap can foster biases and unhealthy behaviors that may accelerate aging. Further research into various aspects of male aging, extending beyond the symptomatology of this period, is worthwhile. Broadening this knowledge can help break stereotypes, encourage healthy behaviors among men, and lead to the development of effective health education programs tailored to them. Physicians and nurses should increase their involvement in educating men about andropause. Currently, andropause screening is not routinely used in clinical practice. We suggest that screening older men for andropause symptoms is important. Such screening can contribute to earlier detection of symptoms associated with andropause, such as fatigue, depression, decreased libido, and other physical and emotional changes.

Limitations of the study

The study groups of men in 2013 and 2023 were relatively small, which may have limited the ability to draw more generalizable conclusions. The participants in this study were not randomly selected, which can lead to a biased sample that is not representative of the studied population. The most significant limitation of not randomly selecting participants is that the results cannot be reliably generalized to the larger population. Selection bias is the most critical issue. When participants are not chosen randomly, a systematic error is introduced because some individuals have a higher or lower chance of being selected. This results in a skewed sample that does not accurately represent the diversity of the target population. Because the sample is not representative, the study’s findings have low external validity. This means that we cannot confidently claim that the conclusions drawn from the sample are true for the entire population. The results are only valid for the specific, and likely biased, group of people who participated.

Conclusions

This study compared men’s perceptions of andropause using data from 2013 and 2023. Over the 10-year period, knowledge of andropause among men remained limited and did not change significantly between the 2 survey years. While the relatively small sample size may limit the generalizability of the findings, a key strength of the study is the use of validated questionnaires administered to respondents from the same geographical area in both 2013 and 2023.

Supplementary data

The supplementary materials are available at https://doi.org/10.5281/zenodo.19554902. The package contains the following files:

Supplementary Table 1. Health assessment of the respondents. This table provides a comparative analysis of respondents self-reported health status and the frequency of seeking medical care between 2013 and 2023.

Supplementary Table 2. Respondents opinions on andropause. This table illustrates changes in the awareness of andropause and the evolving perceptions regarding its symptoms and psychosocial impact on men over a 10-year period.

Supplementary Table 3. Shifting opinions on the benefits of hormone therapy and the increasing willingness of men to undergo such treatment between 2013 and 2023.

Data from 2013 – all the results from the surveys conducted in 2013.

Data from 2023 – all the results from the surveys conducted in 2023.

Data distribution.

Data Availability Statement

The datasets supporting the findings of the current study are openly available in Figshare at https://figshare.com/s/7dd1e59cbb300057d5ad.

Consent for publication of personal information

Not applicable.

Use of AI and AI-assisted technologies

Not applicable.

Tables


Table 1. Male demographics in 2013–2023

Variable

2013

(n = 308)

2023

(n = 349)

p-value

p-value

(post hoc test)

Age, median, Q1–Q3, range [years]

45.0

20–60

18–90

40.0

25–53

18–72

0.004m

Marital status, n (%)

Single

114 (37.0)

142 (40.7)

0.012c

>0.999c

Married

159 (51.6)

190 (54.4)

>0.999c

Widower

18 (5.8)

4 (1.1)

0.004c

Divorced

14 (4.5)

10 (2.9)

>0.999c

Separated

3 (1.0)

3 (0.9)

>0.999f

Place of residence, n (%)

Urban

196 (63.6)

285 (81.7)

<0.001c

Rural

112 (36.4)

64 (18.3)

Persons living in the same household, n (%)

Alone

70 (23.3)

80 (22.9)

<0.001c

>0.999c

With wife

81 (27.0)

113 (32.4)

0.950c

With wife and children

83 (27.7)

76 (21.8)

0.574c

Only with children

9 (3.0)

10 (2.9)

>0.999c

Differently

57 (19.0)

0 (0.0)

<0.001c

With parents

0 (0.0)

22 (6.3)

<0.001f

With partner

0 (0.0)

48 (13.8)

<0.001f

Social and living conditions, n (%)

Very good

69 (22.4)

155 (44.4)

<0.001c

<0.001c

Good

182 (59.1)

156 (44.7)

0.001c

Medium

48 (15.6)

28 (8.0)

0.015c

Poor

4 (1.3)

10 (2.9)

0.992c

Very poor

2 (0.6)

0 (0.0)

>0.999f

Hard to say

3 (1.0)

0 (0.0)

0.615f

Education, n (%)

Secondary

153 (49.7)

112 (32.1)

<0.001c

<0.001c

Vocational

77 (25.0)

12 (3.4)

<0.001c

Bachelor’s degree

22 (7.1)

12 (3.4)

0.162c

Master’s degree

47 (15.3)

213 (61.1)

<0.001c

No answer

9 (2.9)

0 (0.0)

0.005f

Q1, Q3 – 1st and 3rd quartile; m – Mann–Whitney U test; c – χ2 independence test. Post hoc test – χ2 independence test except for tests marked with f – Fisher’s exact test; p-values adjusted for multiple comparisons using the Bonferroni correction.
Table 2. Understanding of old age among respondents

Variable

2013

n = 308

2023

n = 349

p-value

p-value post hoc test

Boundaries of old age, according to the respondents, n (%)

55–60

17 (5.5)

37 (10.6)

0.005c

0.108c

61–65

36 (11.7)

55 (15.8)

0.790c

66–70

60 (19.5)

62 (17.8)

>0.999c

71–75

81 (26.3)

93 (26.6)

>0.999c

≥76

107 (34.7)

102 (29.2)

0.780c

Hard to say

7 (2.3)

0 (0.0)

0.029c

Thinking about old age, n (%)

Yes, frequently

132 (42.9)

206 (59.0)

<0.001c

0.011c

Yes, sometimes

100 (32.5)

78 (22.3)

>0.999c

No

100 (32.5)

65 (18.6)

0.001c

Conviction that old age can be successful, n (%)

Yes

150 (48.7)

269 (77.1)

<0.001c

<0.001c

No

45 (14.6)

29 (8.3)

0.032c

Hard to say

113 (36.7)

51 (14.6)

<0.001c

Identification with chronological age, n (%)

Yes

164 (53.2)

158 (45.3)

<0.001c

0.165c

I say that I am older

49 (15.9)

22 (6.3)

<0.001c

I say that I am younger

25 (8.1)

103 (29.5)

<0.001c

It varies

70 (22.7)

66 (18.9)

0.913c

Willingness to live to a ripe old age, n (%)

Yes

154 (50.0)

204 (58.4)

0.063 c

No

58 (18.8)

62 (17.7)

Hard to say

96 (31.2)

83 (23.8)

c – χ2 independence test. Post hoc test – χ2 independence test p-values adjusted for multiple comparisons using the Bonferroni correction. Values do not sum up to 100 % because participants had the opportunity to answer multiple questions.
Table 3. Symptoms associated with old age reported by respondents

Variables

2013

n = 308

2023

n = 349

p-value

Symptoms associated with old age$, n (%)

Depression

0 (0)

234 (67.0)

 <0.00f

Nervousness, anger

115 (37.3)

0 (0)

<0.00f

Mood swings, irritability

113 (36.7)

129 (37.0)

0.979c

Impaired concentration

108 (35.1)

124 (35.5)

0.992c

Inability to experience joy (anhedonia)

43 (14.0)

139 (39.8)

<0.00c

Discouragement

113 (36.7)

122 (35.0)

0.809c

Increased anxiety

43 (14.0)

0 (0)

<0.00f

Lack of vitality

86 (27.9)

138 (39.5)

0.033c

Fatigue

107 (34.7)

112 (32.1)

0.667c

Loss of self-confidence

60 (19.5)

120 (34.5)

0.002c

Impaired social interactions

77 (25.0)

0 (0)

<0.00f

Physical symptoms associated with old age$, n (%)

Muscle pain

130 (42.2)

124 (35.5)

<0.001c

Joint pain

212 (70.2)

238 (68.2)

0.984c

Excessive sweating

63 (20.5)

0 (0)

<0.001f

Palpitations

119 (38.6)

0 (0)

<0.001f

Hot flashes

43 (14.0)

87 (25.0)

0.005c

Sleep problems

135 (43.8)

113 (32.4)

0.050c

Weakness

71 (25.1)

211 (60.5)

<0.001c

Memory impairment

123 (40.0)

240 (68.8)

<0.001c

Fatigue

0 (0)

165 (47.3)

<0.001f

Decrease in muscular strength

196 (63.6)

123 (35.2)

<0.001c

Sexual dysfunctions in the course of ageing$, n (%)

Decrease in ability to perform sexually

240 (77.9)

321 (92.0)

0.265c

Erectile dysfunction (weak and short-lasting)

166 (53.9)

219 (62.8)

0.197c

Decrease in libido

129 (41.9)

317 (90.0)

<0.001c

Cognitive impairment$, n (%)

Impaired visual perception

178 (57.8)

234 (67.0)

0.266c

Impaired visual attention

151 (49.0)

112 (32.1)

0.004c

Impaired object identification

85 (27.6)

110 (31.5)

0.466c

Impaired spatial attention

76 (24.7)

87 (24.9)

0.976c

Other old age symptoms$, n (%)

Hypertension

175 (56.8)

175 (50.1)

0.308c

Increase in visceral fat

138 (44.8)

206 (59.0)

0.048c

Hair thinning

131 (42.5)

126 (50.1)

0.298c

Osteoporosis

101 (32.8)

0 (0)

<0.001f

Weight loss

77 (25.0)

0 (0)

<0.001f

More frequent visits to physicians/pharmacies

0 (0)

68 (19.5)

<0.001f

More frequent occurrence of various diseases

0 (0)

29 (8.3)

<0.001f

Hearing deterioration

0 (0)

237 (67.9)

<0.001f

Hormonal disorders

0 (0)

132 (37.8

<0.001f

Decrease in hormone levels$, n (%)

Testosterone

236 (76.6)

262 (75.1)

0.298c

Somatotropin

67 (21.8)

79 (22.6)

0.908c

Melatonin

61 (19.8)

109 (31.2)

0.013c

Estradiol

21 (6.8)

19 (5.4)

0.903c

Dehydroepiandrosterone (DHEA)

16 (5.2)

63 (18.1)

<0.001c

$ The total does not have to be 100, as any response options could have been indicated; c – χ2 independence test. Post hoc test – χ2 independence test except for tests marked with f – Fisher’s exact test; p-values adjusted for multiple comparisons using the Bonferroni correction.
Table 4. Health assessment of respondents

Variable

2013

(n = 308)

2023

(n = 349)

p-value

(overall test)

p-value

(post hoc test)

Health assessment of respondents, n (%)

Very good

34 (11.0)

84 (24.1)

<0.001c

<0.001c

Good

122 (39.6)

227 (65.0)

<0.001c

Average

107 (34.8)

30 (8.6)

<0.001c

Poor

34 (11.0)

8 (2.3)

<0.001c

Very poor

1 (0.4)

0 (0)

>0.999f

Hard to say

10 (3.2)

0 (0)

0.003f

Frequency of seeking medical care, n (%)

Once a week

1 (0.3)

0 (0)

<0.001c

>0.999f

Several times a month

15 (5.0)

0 (0)

<0.001c

Once a month

46 (15.2)

22 (6.5)

0.003c

Every 6 months

25 (8.3)

71 (20.9)

<0.001c

Once a year

0 (0.0)

24 (7.1)

<0.001c

Several times a year

57 (18.9)

33 (9.4)

>0.999c

When needed

144 (47.7)

159 (46.8)

>0.999c

Differently

14 (4.6)

0 (0)

<0.001c

c – χ2 independence test. Post hoc test – χ2 independence test except for tests marked with f – Fisher’s exact test; p-values adjusted for multiple comparisons using the Bonferroni correction.
Table 5. Respondents’ opinions on andropause

Variable

2013

n = 308

2023

n = 349

p-value overall test

p-value

post hoc test

Declaration of knowing what ‘andropause’ means, n (%)

Yes

133 (43.2)

306 (87.7)

<0.001c

<0.001c

No

120 (39.0)

43 (12.3)

<0.001c

Not sure

55 (17.8)

0 (0)

<0.001c

Opinions on andropause$, n (%)

It is something natural

106 (34.4)

205 (58.7)

<0.001c

Its effects vary among individuals

92 (29.9)

70 (20.1)

0.029c

Something inevitable after the age of 50

89 (28.9)

56 (16.0)

0.002c

Something that causes lowering of mood

57 (18.5)

45 (12.9)

0.112c

It affects individuals who have not taken care of themselves

44 (14.3)

7 (2.0)

<0.001c

It is a disease

49 (15.9)

42 (12.0)

0.557c

It is a punishment for an unhealthy lifestyle

24 (7.8)

7 (2.0)

0.002c

Inability to have sexual intercourse

54 (7.5)

21 (6.0)

<0.001c

It requires hospitalization

14 (4.5)

0 (0)

0.002f

It is a mental disorder

14 (4.5)

0 (0)

0.002f

It prevents individuals from continuing work

12 (3.9)

0 (0)

0.002f

A figment of scientists and/or pharmaceutical companies

10 (3.2)

0 (0)

0.002f

It is the end of life

6 (1.0)

0 (0)

0.029f

Time of change for the better

0 (0)

21 (6.0)

<0.001f

Time to pass on experiences, values

0 (0)

35 (10.0)

<0.001f

Time to develop interests and fulfil dreams

0 (0)

21 (6.0)

<0.001f

Time to help children/grandchildren

0 (0)

14 (4.0)

0.001f

Time for social activities

0 (0)

17 (4.9)

<0.001f

Time for rest

0 (0)

21 (6.0)

<0.001f

Hard to say

84 (27.3)

27 (7.7)

<0.001c

Preferred positive statements about men after andropause$, n (%)

Faithful

58 (18.8)

43 (12.3)

<0.001c

Sensitive

43 (14.0)

97 (27.8)

<0.001c

Professionally active

41 (13.3)

82 (23.5)

0.007c

Calm

37 (12.0)

80 (22.9)

0.003c

Courteous

33 (10.7)

40 (11.5)

0.082c

Good

31 (10.1)

20 (5.7)

0.178c

Tolerant

31 (10.1)

48 (13.8)

0.523c

Agreeable

28 (9.1)

10 (2.9)

0.002c

Fun-loving

25 (8.1)

0 (0)

<0.001f

Sexually active

24 (7.8)

34 (9.7)

0.268c

Masculine

22 (7.1)

12 (3.4)

0.132c

Curious

20 (6.5)

17 (4.9)

0.749c

Fit

18 (5.8)

9 (2.6)

0.131c

Patient

16 (5.2)

0 (0)

<0.001f

Confident

14 (4.5)

41 (11.7)

0.003c

Composed

14 (4.5)

0 (0)

0.002f

Hard to say

147 (47.7)

0 (0)

<0.001f

Preferred negative statements about men after andropause$, n (%)

Sexually inactive

83 (26.9)

151 (42.3)

0.003c

Argumentative

66 (21.4)

54 (15.5)

0.358c

Short-tempered

59 (19.2)

102 (29.2)

0.024c

Irritable

54 (17.5)

106 (30.4)

0.004c

Sulky

42 (13.6)

80 (22.9)

0.014c

Unfit

42 (13.6)

125 (35.8)

<0.001c

Indifferent, cold

36 (11.7)

108 (30.9)

<0.001c

Inferiority complex

36 (11.7)

90 (25.8)

<0.001c

Serious

30 (9.7)

62 (17.8)

0.014c

Poor

28 (9.1)

36 (10.3)

0.418c

Professionally inactive

27 (8.8)

45 (12.9)

0.061c

Arrogant

21 (6.8)

13 (3.7)

0.242c

Prejudiced

21 (6.8)

33 (9.5)

0.157c

Having no hobbies

14 (4.5)

34 (9.7)

0.008c

Effeminate

13 (4.2)

25 (7.2)

0.086c

Unfaithful

10 (3.2)

20 (5.7)

0.112c

Hard to say

108 (35.1)

0 (0)

<0.001f

$ the total does not have to be 100, as any response options could have been indicated; c – χ2 independence test. Post hoc test – χ2 independence test except for tests marked with f – Fisher’s exact test; p-values adjusted for multiple comparisons using the Bonferroni correction.
Table 6. Opinions on the use of hormone therapy in men with andropause

Variable

2013

(n = 308)

2023

(n = 349)

p-value

p-value

(post hoc test)

Assessment of benefits from treatment, n (%)

Yes

64 (20.8)

158 (45.3)

<0.001c

<0.001c

No

63 (20.5)

64 (18.3)

0.641c

Not sure

181 (58.7)

127 (36.4)

<0.001c

Effects of hormone therapy in men, n (%)

It improves quality of life

141 (45.8)

143 (41.0)

0.478c

It improves mood

107 (34.7)

134 (38.4)

0.558c

It improves sleep

67 (21.8)

156 (44.7)

<0.001c

It restores morning erections

56 (18.2)

147 (42.1)

<0.001c

It reduces fat mass

43 (14.0)

191 (54.7)

<0.001c

It increases lean body mass

36 (11.7)

150 (43.0)

<0.001c

It significantly lowers cholesterol

35 (11.4)

120 (34.4)

<0.001c

It increases bone mineral density

29 (9.4)

140 (40.1)

<0.001c

It significantly lowers LDL cholesterol

26 (8.4)

0 (0.0)

<0.001f

It reduces insulin resistance

22 (7.1)

80 (22.9)

<0.001c

It significantly lowers insulin

18 (5.8)

20 (5.7)

0.913c

Hard to say

78 (25.3)

121 (34.7)

0.067c

Declaration of willingness to undergo hormone therapy, n (%)

Yes

53 (17.2)

171 (49.0)

<0.001c

<0.001c

No

82 (26.6)

86 (24.6)

>0.999c

Not sure

173 (56.2)

92 (26.4)

<0.001c

c – χ2 independence test. Post hoc test – χ2 independence test except for tests marked with f – Fisher’s exact test; p-values adjusted for multiple comparisons using the Bonferroni correction; LDL – low-density lipoprotein.
Table 7. Values obtained from standardized scales

Scales

2013

(n = 308)

2023

(n = 349)

p-value

Life satisfaction (SWLS)

Median score (Q1, Q3)

24.0 (21, 28)

24.0 (21, 28)

0.788m

Self-efficacy according to the GSES scale

Median score (Q1, Q3)

30.0 (26, 40)

7.0 (5, 9)

<0.001m

Depression risk assessment using the Beck Depression Inventory (BDI)

Median score (Q1, Q3)

4.0 (1, 11.5)

30.9 (26, 38)

<0.001m

Health Behavior Inventory (IHB)

Median score (Q1, Q3)

76.0 (69, 85.5)

68.0 (57, 76)

<0.001m

Andropause as assessed with the Morley scale

No

253 (82.1)

127 (36.4)

<0.001c

Yes

55 (17.9)

222 (63.6)

Symptoms of andropause as assessed with AMS scale

Somatic symptoms

Median score (Q1, Q3)

15.0 (12, 18)

14.3 (10, 19)

0.028m

Mental symptoms

Median score (Q1, Q3)

9.5 (6, 11)

10.0 (6, 11)

0.157m

Sexual functions

Median score (Q1, Q3)

8.0 (5, 13)

7.0 (5, 13)

0.168m

Comparing numeric variables between groups: m Mann–Whitney test; c – χ2 independence test; p-value is significant at <0.05; Q1 – 1st quartile, Q3 – 3rd quartile; SWLS – Satisfaction with Life Scale; GSES – Generalized Self-Efficacy Scale; AMS – Aging Males Symptoms scale.
Table 8. Self-assessment of knowledge about andropause

Variable

2013

(n = 308)

2023

(n = 349)

p-value

Post hoc test

Main sources of information about andropause, n (%)

Media

70 (22.7)

67 (19.2)

0.421c

Press

48 (15.6)

12 (3.4)

<0.001c

Internet

38 (12.3)

92 (26.4)

<0.001c

High school

29 (9.4)

89 (25.5)

<0.001c

Friends

11 (3.6)

4 (1.1)

0.077f

Family

14 (4.5)

22 (6.3)

0.077c

Physician

26 (8.4)

4 (1.1)

<0.001f

Nurse

7 (2.3)

4 (1.1)

0.424f

Academic textbooks

0 (0)

10 (2.9)

0.008f

Hard to say

91 (29.5)

45 (12.9)

<0.001c

Willingness to learn more about andropause, n (%)

Yes

63 (20.5)

187 (53.6)

<0.001c

<0.001c

No

92 (29.9)

86 (24.6)

0.397c

Not sure

153 (49.7)

76 (21.8)

<0.001c

Preferred educators about andropause$, n (%)

Nurse

45 (14.6)

29 (8.3)

0.031c

Physician

177 (57.7)

135 (38.7)

0.004c

Psychologist

94 (30.5)

243 (69.6)

<0.001c

Sociologist

21 (6.8)

31 (8.9)

0.447c

Educational counsellor

31 (10.1)

38 (10.9)

0.855c

Another male

14 (4.5)

12 (3.4)

0.618c

Wife

24 (7.8)

13 (3.7)

0.498c

$the total does not have to be 100, as any number of response options could have been indicated; c – χ2 independence test. f – Fisher’s exact test; post hoc test – χ2 independence test; p-values adjusted for multiple comparisons using the Bonferroni correction.

References (38)

  1. Królikowska S. Nierówności w stanie zdrowia między kobietami a mężczyznami w kontekście płci biologicznej oraz społeczno-kulturowej. Ann Univ Med Lodzensis Fol Sociol. 2011;39:33–42. http://hdl.handle.net/11089/863.
  2. Anderson KN, Anderson LE, Glanze WD. Mosby’s Medical, Nursing, & Allied Health Dictionary: With U.K. Appendixes and British Spellings. 5th ed. St. Louis, USA: Mosby; 1998. ISBN:978-0-8151-4800-5, 978-0-8151-4631-5, 978-1-55664-566-2.
  3. Eurostat. Ageing Europe: Statistics on population developments. Luxembourg, Luxembourg: Eurostat; 2023. https://ec.europa.eu/eurostat/statistics-explained/SEPDF/cache/80393.pdf.
  4. Coles TM, Curtis LH, Boulware LE. Measuring health. Primary Care Clin Office Pract. 2019;46(4):485–491. doi:10.1016/j.pop.2019.07.002
  5. Singh P. Andropause: Current concepts. Indian J Endocr Metab. 2013;17(9):621. doi:10.4103/2230-8210.123552
  6. Morales A. Andropause (or symptomatic late-onset hypogonadism): Facts, fiction and controversies. Aging Male. 2004;7(4):297–303. doi:10.1080/13685530400016664
  7. Mian AH, Yang DY, Kohler TS. Current management and controversies surrounding andropause. Urol Clin North Am. 2022;49(4):583–592. doi:10.1016/j.ucl.2022.07.003
  8. Diehl M, Wettstein M, Spuling SM, Wurm S. Age-related change in self-perceptions of aging: Longitudinal trajectories and predictors of change. Psychol Aging. 2021;36(3):344–359. doi:10.1037/pag0000585
  9. Hägg S, Jylhävä J. Sex differences in biological aging with a focus on human studies. eLife. 2021;10:e63425. doi:10.7554/eLife.63425
  10. Daly M, Robinson E. Depression and anxiety during COVID-19. Lancet. 2022;399(10324):518. doi:10.1016/S0140-6736(22)00187-8
  11. Juczyński Z. Narzędzia Pomiaru w Promocji i Psychologii Zdrowia. Pracownia Testów Psychologicznych Polskiego Towarzystwa Psychologicznego. Warsaw, Poland: Polskie Towarzystwo Psychologiczne (PTP); 2012. ISBN:978-83-60733-43-1.
  12. Beck AT. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561. doi:10.1001/archpsyc.1961.01710120031004
  13. Morley JE. Testosterone and behavior. Clin Geriatr Med. 2003;19(3):605–616. doi:10.1016/S0749-0690(02)00106-4
  14. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49(9):1239–1242. doi:10.1053/meta.2000.8625
  15. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new ‘aging males’ symptoms’ rating scale. Aging Male. 1999;2(2):105–114. doi:10.3109/13685539909003173
  16. Heinemann LJ. Aging Males’ Symptoms scale: A standardized instrument for the practice. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):34–38. PMID:16760622.
  17. Palsgaard P, Maino Vieytes CA, Peterson N, et al. Healthcare professionals’ views and perspectives towards aging. Int J Environ Res Public Health. 2022;19(23):15870. doi:10.3390/ijerph192315870
  18. Patrizio E, Calvani R, Marzetti E, Cesari M. Physical functional assessment in older adults. J Frailty Aging. 2021;10(2):141–149. doi:10.14283/jfa.2020.61
  19. Freedman A, Nicolle J. Social isolation and loneliness: The new geriatric giants. Approach for primary care. Can Fam Physician. 2020;66(3):176–182. PMID:32165464. PMCID:PMC8302356.
  20. Samipoor F, Pakseresht S, Rezasoltani P, Kazemnajad Leili E. Awareness and experience of andropause symptoms in men referring to health centers: A cross-sectional study in Iran. Aging Male. 2017;20(3):153–160. doi:10.1080/13685538.2017.1298586
  21. Adebajo S, Odeyemi K, Oyediran M, Anorlu R, Wright L. Knowledge and experiences of andropause among men in Lagos, Nigeria. West Afr J Med. 2007;26(2):106–112. PMID:17939310.
  22. Ashat M, Puri S, Singh A, Sarpal SS, Goel NK, Koushal V. Awareness of andropause in males: A North Indian study. Indian J Med Sci. 2011;65(9):379–386. PMID:23508480.
  23. Spetz Holm AC, Fredrikson MG. More than half of the men in a Swedish population of men aged 55, 65 and 75 believe in ‘a male climacteric.’ Aging Male. 2011;14(1):16–20. doi:10.3109/13685538.2010.518177
  24. Yuk YY. Awareness and knowledge of andropause among Chinese males in Hong Kong. Am J Mens Health. 2010;4(3):231–236. doi:10.1177/1557988309335154
  25. Tan HM, Tong SF, Ho CCK. Men’s health: Sexual dysfunction, physical, and psychological health. Is there a link? J Sex Med. 2012;9(3):663–671. doi:10.1111/j.1743-6109.2011.02582.x
  26. Pankowski K. Zadowolenie z życia w roku 2023. Warsaw, Poland: Centrum Badania Opinii Społecznej (CBOS); 2024. https://www.cbos.pl/SPISKOM.POL/2024/K_006_24.PDF.
  27. Pryczek K, Bielawska-Batorowicz E. Polish and Finnish students views on andropause. Part I. Opinions on andropause and knowledge about its symptoms [in Polish]. Przegl Menopauz. 2007;6:357–364. https://www.termedia.pl/Polish-and-Finnish-students-views-on-andro­pause-Part-I-Opinions-on-andropause-and-knowledge-about-its-symptoms,4,9524,1,1.html
  28. Schwarz ER, Phan A, Willix RD. Andropause and the development of cardiovascular disease presentation-more than an epi-phenomenon. J Geriatr Cardiol. 2011;8(1):35–43. doi:10.3724/SP.J.1263.2011.00035
  29. Kalra S, Joshi A, Dhingra A, Dutta D, Das S. Counselling for testosterone therapy in mid-life men. J Midlife Health. 2022;13(2):185–189. doi:10.4103/jmh.jmh_240_20
  30. Zhu Y, Li JH, Zhao J, et al. Assessment of the health status of middle-aged and elderly men with head scale, SF-36, IIEF5, AMS, and IPSS. BMC Geriatr. 2021;21(1):641. doi:10.1186/s12877-021-02595-y
  31. Zheng JB, Liang QF, Li JH, et al. Longitudinal trends of AMS and IIEF-5 scores in randomly selected community men 40 to 80 years old: Preliminary results. J Sex Med. 2019;16(10):1567–1573. doi:10.1016/j.jsxm.2019.07.017
  32. Jankowska EA, Szklarska A, Lopuszanska M, Medras M. Age and social gradients in the intensity of aging males’ symptoms in Poland. Aging Male. 2008;11(2):83–88. doi:10.1080/13685530701778020
  33. Park Y, Park H, Lee J, Yun B, Yoon JH. Association between working after retirement age and lower depressive symptoms among Korean older adults. J Affect Disord. 2025;390:119874. doi:10.1016/j.jad.2025.119874
  34. Hajduk A, Korzonek M, Przybycień K, Ertmański S, Stolarek J. Study of depressiveness with Beck Depression Inventory in patients with cardiac arrhythmias [in Polish]. Ann Acad Med Stetin. 2011;57:45–48. https://www.studocu.com/pl/document/uniwersytet-jagiellonski-collegium-medicum/psych chologia/badanie-depresyjnosci-u-pacjentow-z-arytmia-serca-skala-becka/133796525
  35. Yuan Y, Peng C, Burr JA, Lapane KL. Frailty, cognitive impairment, and depressive symptoms in Chinese older adults: An eight-year multi-trajectory analysis. BMC Geriatr. 2023;23(1):843. doi:10.1186/s12877-023-04554-1
  36. Cengiz Özyurt B. P-450: Prevalence of depressive symptoms in elderly people: Example of a suburban and a rural region in Manisa, Turkey. Eur Geriatr Med. 2015;6(Suppl):S153. doi:10.1016/S1878-7649(15)30547-7
  37. Mohammadi M, Allahverdipour H, Ghanbari Moghaddam A, Matlabi H. The prevalence of andropause and its relationship with sexual quality of life among older Iranian men. Am J Mens Health. 2023;17(2):15579883231161050. doi:10.1177/15579883231161050
  38. Byra S. Poczucie własnej skuteczności w kontekście radzenia sobie w sytuacjach trudnych kobiet i mężczyzn z nabytą niepełnospraw­nością ruchową. Med Og Nauk Zdr. 2011;17(3):127–134. https://www.monz.pl/pdf-73247-10069?filename=Poczucie%20wlasnej.pdf